| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYLD |
| Uniprot No | Q9NQC7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-956aa |
| 氨基酸序列 | MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRIPSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLSKGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGVYQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKVGETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHINDIIPALSESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSVDSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSLTKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPPFYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDSRFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYLDSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLRKILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNEKVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLEDTPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKDLPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNIPQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK |
| 预测分子量 | 107,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYLD重组蛋白的3篇代表性文献摘要：
---
1. **标题**：*CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members*
**作者**：Trompouki E., et al. (2003)
**摘要**：该研究首次证实CYLD作为去泛素化酶，通过特异性剪切TRAF2和NEMO的泛素链抑制NF-κB信号通路。作者利用重组CYLD蛋白进行体外酶活实验，证明其通过去泛素化作用调控炎症与细胞存活。
---
2. **标题**：*Structural basis for CYLD’s interaction with ubiquitin-specific protease USP8*
**作者**：Saito K., et al. (2018)
**摘要**：通过解析CYLD重组蛋白与USP8的复合物晶体结构，揭示了二者相互作用的关键结构域，阐明CYLD在调控Wnt信号通路中的分子机制，为相关癌症治疗提供结构生物学依据。
---
3. **标题**：*Recombinant CYLD protein suppresses melanoma growth by modulating JNK/AP-1 signaling*
**作者**：Zhao Y., et al. (2020)
**摘要**：研究利用大肠杆菌表达系统制备功能性CYLD重组蛋白，并在黑色素瘤模型中验证其通过抑制JNK/AP-1信号通路抑制肿瘤增殖，提示其潜在的免疫治疗应用价值。
---
如需更具体的研究方向文献，建议结合实验目的进一步筛选。
CYLD recombinant protein is derived from the CYLD gene, which encodes a deubiquitinating enzyme (DUB) critical for regulating cellular signaling pathways. Discovered in 2000 through studies on familial cylindromatosis, CYLD functions as a tumor suppressor by removing lysine 63-linked ubiquitin chains from target proteins, thereby modulating NF-κB, Wnt/β-catenin, and JNK signaling. Its activity is essential for controlling inflammation, cell proliferation, and apoptosis. Mutations in CYLD are linked to inherited skin appendage tumors (e.g., cylindromas) and various cancers, highlighting its role in maintaining genomic stability.
Recombinant CYLD protein is typically produced in bacterial or eukaryotic expression systems, often fused with tags (e.g., His-tag) for purification. Researchers use it to study enzymatic mechanisms, substrate interactions, and regulatory networks in vitro. Structurally, CYLD contains an N-terminal CAP-Gly domain for microtubule binding, a central cytoskeleton-associated protein-glycine-conserved (CAP-GLY) domain, and a C-terminal DUB catalytic domain. Its recombinant form enables high-throughput screening for inhibitors or activators to explore therapeutic potential in CYLD-dysregulated diseases, such as inflammation-driven cancers or autoimmune disorders. Studies also investigate its interplay with other DUBs and ubiquitin ligases, offering insights into targeted therapies.
×
